Q-omics provides the consensus-scored TMPRSS6 profile across patient tissues and cancer cell-line models. TMPRSS6 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TMPRSS6 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, TMPRSS6 RNA expression shows 16,672 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, THCA, and UVM as cancer lineages where TMPRSS6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMPRSS6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMPRSS6 survival associations across molecular data types. TMPRSS6 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMPRSS6 RNA expression–survival associations across cancer types. High TMPRSS6 expression shows unfavorable associations in KIRC, UVM, ACC and UCEC, but favorable associations in BLCA and READ. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TMPRSS6 RNA expression.
This table summarizes TMPRSS6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for TMPRSS6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMPRSS6 shows lower tumor expression in KICH, UCEC and LUSC and higher tumor expression in THCA, BRCA and KIRP. The THCA box plot shows higher TMPRSS6 RNA expression in tumor versus normal tissue (log2 FC = +6.047, t-test p < 0.001).
This table shows molecular features associated with TMPRSS6 in patient tissues and cancer cell lines. In patient samples, TMPRSS6 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TMPRSS6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
